RxDoctor Payments Data

Eliana Cuellar

Nurse Practitioner · Fall River, MANPI 1457966806

Payments from drug & device makers

$951in general payments, 2019–2025

Across 39 payments — averaging $24.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$178
  • Lilly USA, LLC$158
  • GSK$118
  • Verona Pharma, Inc.$88
  • Otsuka America Pharmaceutical, Inc.$74
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$73
  • plus $262 from 9 others

What the payments were for

  • Food & beverage$951100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$951 in reported general payments places this provider in the 90th percentile of 3,855 nurse practitioner providers in Massachusetts.

See all nurse practitioner providers in Massachusetts

Medicare billing

Part B allowed, 2024
$109,124
Medicare patients
569
Services billed
1,409

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban30$20,336
OzempicSemaglutide13$16,064
JardianceEmpagliflozin13$7,470
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen82$2,025
Albuterol Sulfate HfaAlbuterol Sulfate50$1,440
Lisinopril97$1,053
Ventolin HfaAlbuterol Sulfate15$849
Fluticasone Propionate43$822
Valsartan20$760
Amlodipine Besylate119$709
Metoprolol Succinate49$685
Simvastatin47$669
Atorvastatin Calcium79$652
Omeprazole43$650
SynthroidLevothyroxine Sodium15$636

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$15$20,33630 claims
Novo NordiskOzempic$15$16,06413 claims
AbbVieSynthroid$36$63615 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,855 nurse practitioner providers in Massachusetts.

Other nurse practitioner in Fall River

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →